Concomitant capecitabine with hepatic delivery of drug eluting beads in metastatic colorectal cancer

• Published in: Anticancer research Vol. 34; no. 12; pp. 7239 - 7245
• Main Authors: Akinwande, Olaguoke, Miller, Amanda, Hayes, David, O'Hara, Ryan, Tomalty, Dana, Martin, Robert C G
• Format: Journal Article
• Language: English
• Published: Greece 01.12.2014
• Subjects: Aged; Aged, 80 and over; Antimetabolites, Antineoplastic - therapeutic use; Antineoplastic Agents, Phytogenic - therapeutic use; Camptothecin - administration & dosage; Camptothecin - analogs & derivatives; Camptothecin - therapeutic use; Capecitabine; Colorectal Neoplasms - drug therapy; Colorectal Neoplasms - mortality; Colorectal Neoplasms - pathology; Deoxycytidine - analogs & derivatives; Deoxycytidine - therapeutic use; Drug Carriers; Female; Fluorouracil - analogs & derivatives; Fluorouracil - therapeutic use; Humans; Infusions, Intra-Arterial; Liver - pathology; Liver Neoplasms - drug therapy; Liver Neoplasms - secondary; Male; Microspheres; Middle Aged; toxicity; Irinotecan; capecitabine; chemoembolization; drug-eluting-beads
• ISSN: 1791-7530

Effectiveness and toxicity of transcatheter arterial injection of irinotecan-eluting beads (DEBIRI) with and without concurrent capecitabine in pre-treated patients with metastatic colorectal cancer (CRC). An Institutional Review Board-approved, multi-institutional registry from 5/2008 to 8/2013 was reviewed. Patients who received DEBIRI with (X-DEBIRI) or without (DEBIRI) capecitabine were compared. Twenty-two X-DEBIRI and 149 DEBIRI patients were compared. There was no difference in the two groups with regards to adverse events (p=0.56). During a 3- and 6-month evaluation, the disease control rate (DCR) was similar in both groups. During the 12-month evaluation, there was better DCR in the X-DEBIRI group (p=0.03). Median survival was 13 months in the DEBIRI group and 22 months in the X-DEBIRI group (log-rank test, p=0.217). There is no additional toxicity when adding capecitabine with DEBIRI. Concurrent capecitabine may offer more durable disease control rate compared to DEBIRI-alone. Survival benefit with concurrent capecitabine was not statistically significant but there may be a trend towards improved survival.